Skip to Main Content
Our Commitment to Diversity

K&L Gates Advises Ridgemont Equity Partners on Acquisition of Tech-Enabled Medical Products Distributor

6 October 2017
Charlotte - Global law firm K&L Gates LLP advised Ridgemont Equity Partners, a middle market private equity investor, on the acquisition of HemaSource Intermediate Holdings, LLC (“HemaSource” or the “Company”), the leading technology-enabled distributor of medical products to the plasma collection industry.

HemaSource, headquartered in Utah, distributes consumable products across 1,300 stock keeping units from two strategically located distribution centers. The Company utilizes a proprietary cloud-based inventory management and business intelligence software solution to help its customers gain supply chain efficiencies and decrease their plasma collection costs.

Ridgemont Equity Partners is a Charlotte-based middle market buyout and growth equity investor. Since 1993, the principals of Ridgemont have invested over $3.5 billion in 140 companies. The firm focuses on investments of $25 million to $100 million in industries in which it has deep expertise, including basic industries and services, energy, health care, and telecommunications/media/technology.

K&L Gates’ cross-practice, cross-office team was led by Rick Giovannelli and John Blair and also included James Fajkowski, Michael Hinckle, Christine Hoke, Mary Scott Kennedy, David Lindsay, Jared Mobley and Richard Nettles among others.

K&L Gates is a fully integrated global law firm with lawyers located across five continents. The firm represents leading multinational corporations, growth and middle-market companies, capital markets participants and entrepreneurs in every major industry group as well as public sector entities, educational institutions, philanthropic organizations and individuals.

Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel